Rui Avelar Sells 27,904 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Rui Avelar also recently made the following trade(s):

• On Monday, December 23rd, Rui Avelar sold 2,252 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total transaction of $24,434.20.

Evolus Price Performance

Shares of Evolus stock traded down $0.03 on Monday, hitting $13.00. The company's stock had a trading volume of 527,427 shares, compared to its average volume of 591,935. The company has a market capitalization of $826.63 million, a price-to-earnings ratio of -14.29 and a beta of 1.28. Evolus, Inc. has a 1 year low of $9.25 and a 1 year high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a fifty day moving average price of $13.42 and a 200-day moving average price of $13.87.

Analysts Set New Price Targets

EOLS has been the topic of several analyst reports. Barclays increased their price target on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Finally, HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th.

Remove Ads

Hedge Funds Weigh In On Evolus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. Oppenheimer & Co. Inc. acquired a new position in shares of Evolus during the 3rd quarter worth about $212,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Evolus during the third quarter valued at approximately $940,000. Intech Investment Management LLC purchased a new position in shares of Evolus in the third quarter valued at approximately $228,000. Charles Schwab Investment Management Inc. increased its position in shares of Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company's stock worth $6,781,000 after purchasing an additional 265,635 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Evolus during the third quarter worth approximately $191,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.